|
Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus Clinical research trials and Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus. Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus clinical trial. Subjects often receive the most expert healthcare possible for their Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus  Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus
Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus
For Condition: Thrombocytopenia
Status: Completed
Sponsor(s): Warren G Magnuson Clinical Center (CC) ,
Synopsis: Plasma histidine-rich glycoprotein (HRG) binds to platelets in the presence of zinc (1). This binding is totally blocked by a monoclonal antibody directed against platelet membrane CD36. Therefore, CD36 is assumed to carry the platelet binding site for HRG (2). Because CD36 also has a variety of other ligands, including polyanionic lipids, it is also possible that it contains the binding site for heparin (also polyanionic) and might be involve in the pathogenesis of heparin-induced thrombocytopenia. Demonstrating absent HRG or heparin binding to platelets lacking CD36 would confirm that the binding sites for either or both of these ligands are located on this membrane protein. Because 3% to 11% of healthy Japanese are reported to lack CD36 on their platelets, this population is a practical source of cells for examining the physiologic role(s) for CD36. Therefore, we will recruit blood donors from the Japanese community on the NIH campus. Their platelets will tested for the presence of CD36. Recruitment will be closed after two individuals have been identified whose platelets lack CD36 and who are willing to donate 30 cc of blood on 4 or 5 subsequent occasions for binding studies with radiolabeled HRG and heparin.
Details: Plasma histidine-rich glycoprotein (HRG) binds to platelets in the presence of zinc (1). This binding is totally blocked by a monoclonal antibody directed against platelet membrane CD36. Therefore, CD36 is assumed to carry the platelet binding site for HRG (2). Because CD36 also has a variety of other ligands, including polyanionic lipids, it is also possible that it contains the binding site for heparin (also polyanionic) and might be involved in the pathogenesis of heparin-induced thrombocytopenia. Demonstrating absent HRG or heparin binding to platelets lacking CD36 would confirm that the binding sites for either or both of these ligands are located on this membrane protein. Because 3% to 11% of healthy Japanese are reported to lack CD36 on their platelets, this population is a practical source of cells for examining the physiologic role(s) for CD36. It has also been reported that 2.4% of African Americans and 4% of Taiwanese lack this protein on their platelets. Therefore, we will recruit blood donors from the Japanese, African American, and Taiwanese community on the NIH campus. Their platelets will be tested for the presence of CD36. Recruitment will be closed after two individuals have been identified whose platelets lack CD36 and who are willing to donate 30 cc of blood on 4 or 5 subsequent occasions for binding studies with radiolabeled HRG and heparin.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Phase I: Full Japanese, African American, and Taiwanese ancestry At least 18 years of age. Willingness and ability to participate in Phase II of the study. Must be able to provide written informed consent. Phase II: Less than 1% CD36 present on platelets, compared with controls. EXCLUSION CRITERIA: Phase I: A history of anemia or thrombocytopenia. Unwillingness or inability to participate in Phase II of the study. Phase II: Discovery of anemia (hemoglobin less than 11.1 g/dL for women, less than 12.7 for men) or thrombocytopenia (less than 162,000/microliter for women, less than 154,000/microliter for men) in the blood counts performed during Phase I. Subjects will not be excluded because of any medications.
Total Enrollment: 150
Location and Contact Information:
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 010156; 01-CC-0156
Study Start Date: April 23, 2001
Record last reviewed: February 16, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00015639
Other Thrombocytopenia Studies:
1. Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
2. Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy
3. Treatment of Autoimmune Thrombocytopenia (AITP)
4. Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Cyclosporine
5. Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes
Related Studies:
Other Thrombocytopenia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus
|
|
|
|
|
|
|
|
